1Smith CA, Gruss HJ, Davis T, et al. CD30 antigen, a marker for Hodgkin' s lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF [ J ]. Cell, 1993, 73(7) : 1 349 - 1 360.
2Falini B, pileri S, Pizzolo G, et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy[J ]. Blood, 1995, 85(1):1- 14.
3Del Prete G, De C, arli M, Almerigogna F, et al. Preferential expression of CD30 by human CD4^+ T cells producing Th2 - type cytokines[J]. FASEB J, 1995,9(1):81- 86.
4Bengtsson AE, Johansson C, Tengvall LM, et al. Not only Th2 cells but also Th1 and Th0 cells express CD30 after activation[J ]. J Leukoc Biol, 1995, 58(2) :683 - 689.
5Shimozato O, Takeda K, Yagita H, et al. Expression of CD30 ligand (CD153) on murine activated T cells[J]. Biochem Biophys Res Commun, 1999, 256(6):519- 526.
6Younes A, Consoli U, Zhao S, et al. CD30 ligand is expressed on resting normal and malignant human B lymphocytes [ J ]. Br J Haematol, 1996, 93(3) :569 - 571.
7Cerutti A, Schaffer A, Goodwin RG, et al. Engagement of CD153 (CD30 liganA) by CD30^+ T cells inhibits class switch DNA recombination and antibody production in human IgD^+ IgM^+ B celLs[J]. J Immunol, 2000, 165(2) : 786 - 794.
8Josimovie AO, Durkop H, Schwarting R, et al. Ki-1(CD30) antigen is released by Ki-1 - positive tumor cells in vitro and in vivo. Ⅰ. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in sertan by an enzyme-linkedimmunosorbent assay[J ]. Eur J Immunol, 1989, 19(1) : 157 - 162.
9Horie R, Watanabe T. CD30 Expression and function in health and disease[J ]. Semin Immunol, 1998, 10(6) : 457 - 470.
10Younes A, Consoli U, Snell V, et al. CD30 ligand in lymphoma patients with CD30 tumors[J]. J Clin Onco, 1997, 15(11): 3 355 - 3 362.
